Company profile
Biomind Labs Inc.
OTC: BMNDF · Healthcare · Biotechnology
Canadian filerHQ Canelones, Reports USD
#1163 of 1,418 Healthcare companies by revenue
EA Score
——FH 2DQ —GM —SS 28
v0.1 · 35/100 weight · pillars only
↑ disclosure history, market scale · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$865.3k
Employees
5
as of 2026-09-01
Market cap
$19.4M
as of 2026-09-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$865.3k-$865.3k2025
Operating income-$861.4k-$861.4k2025
Total assets$36$362025
Liabilities$1.7M$1.7M2025
Equity-$1.7M-$1.7M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Biomind Labs Inc.’s revenue?
Biomind Labs Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Palatin Technologies, Inc.40DEOM Pharmaceuticals Holdings, Inc.——Resverlogix Corp.——Ocumetics Technology Corp.——BioCardia, Inc.29DTvardi Therapeutics, Inc.35DKey facts
CEOAlejandro Antalich
SectorHealthcare
IndustryBiotechnology
HeadquartersCanelones, null
ExchangeOTC: BMNDF
Employees5
IPO date2021-07-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.